Molecular Imaging in the Head and Neck: Diagnosis and Therapy.
Publication
, Journal Article
Howard, BA
Published in: Radiol Clin North Am
November 2020
This article is a summary of the most up-to-date applications of radiopharmaceuticals to the diagnosis and therapy of benign and malignant diseases involving endocrine or neuroendocrine organs of the head and neck, focusing on radiotracers approved by the US Food and Drug Administration, such as I-123- and I-131-sodium iodide, F-18-fluorodeoxyglucose, Tc99m-sestamibi, as well as the more recently approved tracers Ga-68 DOTATATE and Lu-177 DOTATATE.
Duke Scholars
Published In
Radiol Clin North Am
DOI
EISSN
1557-8275
Publication Date
November 2020
Volume
58
Issue
6
Start / End Page
1135 / 1146
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Sensitivity and Specificity
- Radiopharmaceuticals
- Positron-Emission Tomography
- Organometallic Compounds
- Nuclear Medicine & Medical Imaging
- Neuroendocrine Tumors
- Molecular Imaging
- Male
Citation
APA
Chicago
ICMJE
MLA
NLM
Howard, B. A. (2020). Molecular Imaging in the Head and Neck: Diagnosis and Therapy. Radiol Clin North Am, 58(6), 1135–1146. https://doi.org/10.1016/j.rcl.2020.08.001
Howard, Brandon A. “Molecular Imaging in the Head and Neck: Diagnosis and Therapy.” Radiol Clin North Am 58, no. 6 (November 2020): 1135–46. https://doi.org/10.1016/j.rcl.2020.08.001.
Howard BA. Molecular Imaging in the Head and Neck: Diagnosis and Therapy. Radiol Clin North Am. 2020 Nov;58(6):1135–46.
Howard, Brandon A. “Molecular Imaging in the Head and Neck: Diagnosis and Therapy.” Radiol Clin North Am, vol. 58, no. 6, Nov. 2020, pp. 1135–46. Pubmed, doi:10.1016/j.rcl.2020.08.001.
Howard BA. Molecular Imaging in the Head and Neck: Diagnosis and Therapy. Radiol Clin North Am. 2020 Nov;58(6):1135–1146.
Published In
Radiol Clin North Am
DOI
EISSN
1557-8275
Publication Date
November 2020
Volume
58
Issue
6
Start / End Page
1135 / 1146
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Sensitivity and Specificity
- Radiopharmaceuticals
- Positron-Emission Tomography
- Organometallic Compounds
- Nuclear Medicine & Medical Imaging
- Neuroendocrine Tumors
- Molecular Imaging
- Male